Cencora, Inc.'s Stock Analysis

Cencora Announces $3.5 Billion Merger with Covetrus

Cencora has entered into a definitive agreement to merge its animal health business, MWI Animal Health, with Covetrus, Inc. The merger values MWI at an enterprise value of $3.5 billion, with Cencora set to receive $1.25 billion in cash, along with $800 million in preferred equity and $1.45 billion in common equity in the new combined entity. Following the merger, Cencora will hold a 34.3% ownership stake in CVET TopCo, LP, the parent company of Covetrus.

The completion of the transaction is contingent upon customary closing conditions, including necessary regulatory approvals. Cencora has indicated that its fiscal 2026 financial guidance does not currently account for the merger's completion within that fiscal year. The transaction aims to enhance service offerings and operational efficiencies within the animal health sector, benefiting stakeholders across the supply chain.

Feb 18, 2026 07:34:15

Cencora Raises $3 Billion Through Senior Notes Offering

Cencora, Inc. has successfully completed a public offering of $3.0 billion in Senior Notes, which include five tranches with varying interest rates and maturities. The notes consist of $500 million of 3.950% notes due in 2029, $500 million of 4.250% notes due in 2030, $500 million of 4.600% notes due in 2033, $1 billion of 4.900% notes due in 2036, and $500 million of 5.650% notes due in 2056. The company plans to use the net proceeds primarily to repay outstanding amounts under its 364-Day Term Credit Agreement related to its acquisition of OneOncology and for general corporate purposes.

The Senior Notes are unsecured and rank equally with Cencora’s existing and future unsecured debt. They are subject to certain covenants that limit the company’s ability to incur additional debt, create liens, or engage in significant asset transactions. Events of default include nonpayment of principal or interest and breaches of covenants. The company has filed the relevant indentures and prospectus with the SEC, and the offering was managed by Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo.

Feb 13, 2026 16:36:38

Cencora Prices $3 Billion in Senior Notes Offering

Cencora, Inc. has announced the pricing of $3 billion in senior notes through a public offering. This includes five different series of notes with varying interest rates and maturities ranging from 2029 to 2056. The offering is expected to close on February 13, 2026, and is registered under an effective shelf registration statement filed with the SEC.

The company plans to use the net proceeds of approximately $2.98 billion from this offering to repay outstanding amounts under a recent credit agreement related to its acquisition of OneOncology, with any remaining funds allocated for general corporate purposes. The underwriting process involves several major financial institutions, including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo, which have previously engaged with Cencora in various capacities.

Feb 11, 2026 17:00:08

Cencora Revises Financial Reporting Structure for Investor Clarity

Cencora, Inc. has announced a revision to its financial reporting structure, effective from the first quarter of fiscal 2026. This change follows a strategic review aimed at aligning the company’s operations with its growth priorities. The new structure includes three segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. segment focuses on U.S. Human Health, while the International segment encompasses various global operations. The 'Other' category includes businesses currently exploring strategic alternatives.

The company filed this revision as part of its Current Report on Form 8-K to update previously reported segment results in its Annual Report for the fiscal year ending September 30, 2025. This update does not alter the company's audited consolidated financial statements but reflects the impact of the new reporting structure. Investors are encouraged to refer to the upcoming Quarterly Report for developments following the fiscal year 2025 filings.

Feb 10, 2026 08:46:43

Cencora Reports Q1 2026 Earnings and OneOncology Acquisition Details

Cencora, Inc. reported a revenue of $85.9 billion for the first quarter of fiscal 2026, marking a 5.5% increase compared to the same period last year. The company achieved a diluted earnings per share (EPS) of $2.87, up 14.8% from $2.50 in the prior year. Adjusted diluted EPS also increased by 9.4% to $4.08. The company raised its adjusted operating income guidance to a growth range of 11.5% to 13.5% following the completion of its acquisition of OneOncology, which will be consolidated within the U.S. Healthcare Solutions segment.

In addition to financial results, Cencora announced the acquisition of the majority equity interests in OneOncology for approximately $4.6 billion, financed through new debt. The U.S. Healthcare Solutions segment generated $76.2 billion in revenue, a 5.0% increase driven by market growth, while the International Healthcare Solutions segment reported $7.6 billion in revenue, a 9.6% increase. The company declared a quarterly cash dividend of $0.60 per share, payable on March 2, 2026, to shareholders of record by February 13, 2026.

Feb 04, 2026 06:31:44

Cencora Appoints Ellen Cooper to Board of Directors

Cencora, Inc. has appointed Ellen G. Cooper as a new independent director, effective January 20, 2026. The Board of Directors has increased its membership from ten to eleven members to accommodate this appointment. Ms. Cooper, who is currently the Chairman, President, and CEO of Lincoln Financial, will receive compensation in line with other non-employee directors, pro-rated until the 2026 Annual Meeting of Stockholders. There are no disclosed arrangements or family relationships that would require further disclosure regarding her appointment.

The company announced Ms. Cooper's election through a news release on January 22, 2026. Her extensive background in risk management and leadership within regulated industries is expected to enhance the Board's effectiveness in guiding Cencora's growth. Cencora is recognized as a leading pharmaceutical solutions organization, ranking #10 on the Fortune 500 and #18 on the Global Fortune 500, with annual revenues exceeding $300 billion.

Jan 22, 2026 08:00:41

Cencora Secures $5.5 Billion Credit Facility for Acquisition

Cencora, Inc. has entered into an amendment to its revolving credit facility, increasing the total commitments to $5.5 billion. This amendment, effective January 12, 2026, will support the company’s liquidity and financing needs. Additionally, the company has established a $1.5 billion senior unsecured term loan facility and a $3.0 billion 364-day term loan facility, both intended to finance the acquisition of OneOncology and to refinance existing debt of the target company.

The new financing arrangements include specific covenants regarding financial leverage and limitations on indebtedness. The terms of the loans will be influenced by the company’s public debt ratings, with interest rates tied to the Term SOFR rate and other benchmarks. The completion of these loans has resulted in the cancellation of previously arranged bridge financing commitments amounting to $4.5 billion. The company has also engaged various financial institutions for advisory services related to the acquisition.

Jan 16, 2026 16:01:01

Cencora to Acquire OneOncology for Approximately $5 Billion

Cencora, Inc. has announced a definitive agreement to acquire the majority of the outstanding equity interests in OneOncology from TPG and other shareholders for approximately $3.6 billion, along with the retirement of its existing corporate debt totaling $1.3 billion, bringing the total cash consideration to around $5 billion. This acquisition aims to enhance Cencora's management services organization and is expected to close by the end of the second quarter of fiscal 2026, pending regulatory approvals. The transaction will be funded through new debt financing, with Cencora securing $4.5 billion in bridge financing commitments.

The acquisition values OneOncology at $7.4 billion, with an equity value of about $6 billion. While Cencora's fiscal 2026 guidance does not reflect the impact of this acquisition, the company has indicated that the deal is expected to be approximately neutral to its adjusted diluted earnings per share in the first year following the close. Additionally, Cencora is pausing share repurchases in light of the acquisition and is raising its long-term guidance for adjusted operating income and diluted EPS to account for the anticipated contributions from OneOncology.

Dec 15, 2025 07:00:45

Cencora Reports Q4 and Fiscal Year 2025 Financial Results

Cencora, Inc. reported a revenue of $83.7 billion for the fourth quarter of fiscal year 2025, marking a 5.9 percent increase year-over-year. The company also achieved a fiscal year revenue of $321.3 billion, a 9.3 percent increase from the previous year. However, the diluted earnings per share (EPS) for the fourth quarter was $(1.75), a decline from $0.02 in the prior year, while the adjusted diluted EPS rose to $3.84, reflecting a 15.0 percent increase. The company announced a 9 percent increase in its quarterly dividend to $0.60 per share, payable on December 1, 2025, and raised its long-term guidance expectations, indicating confidence in future growth prospects.

Recently, Cencora underwent a strategic review and reorganized its reporting structure into three segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions segment saw a revenue increase of 5.7 percent, while International Healthcare Solutions revenue grew by 7.6 percent. The company plans to invest $1 billion through 2030 to enhance its distribution network and increase capacity, which could positively impact its operational resilience and growth in specialty pharmaceuticals.

Nov 05, 2025 06:33:58

Cencora Amends Term Loan and Money Market Facility Agreements

Cencora, Inc. has amended its Term Credit Agreement, changing the maturity date of its senior unsecured term loan from January 2, 2028, to October 1, 2027. The amendment also modifies the interest rate structure, which is now based on either an adjusted Term SOFR rate or an alternate base rate, with applicable margins determined by the company's public debt ratings.

Additionally, Cencora amended its Money Market Facility Agreement, allowing for short-term, unsecured revolving credit loans. The amendment permits borrowings of up to $500 million from April 1 to December 1 and up to $750 million from December 1 to March 31. The facility can be decreased or terminated at any time by either the bank or the company without prior notice.

Sep 09, 2025 17:00:34